CAR T-cell therapy is new treatment option for patients with certain types of non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma who relapsed or did not respond to other treatments. This presentation discusses who is eligible to receive CAR T-cell therapy, what the procedure entails and potential side effects.

Fatigue is the most common complaint of patients. It can continue for years after treatment. It may be due to the disease itself, or the chemotherapy, radiation, and other medications used to treat the disease. This presentation reviews the causes and complications of transplant-related fatigue and describes lifestyle changes and pharmacological interventions that can improve cancer-related fatigue.

Multiple myeloma is the most common cancer of the bone marrow. This presentation discusses transplant options and drug therapies for treating myeloma. It also reviews options for maintenance therapy and responding to relapses.

Autologous stem cell transplants use the patient’s own stem cells to rescue him or her from the effects of high-dose chemotherapy. This type of transplant is most often used to treat patients with multiple myeloma, non-Hodgkin lymphoma and Hodgkin lymphoma. This presentation discusses the transplant process, and common early and late complications.

A stem cell transplant can be emotionally challenging and disrupt normal life and relationships, at least for a time. Acknowledging these challenges and cultivating social and professional support can help restore emotional health. This presentation describes common emotions patients feel after transplant and some effective methods for coping with them.

The number of long-term survivors of hematopoietic cell transplants (bone marrow, stem cell, and cord blood) is dramatically increasing. However, up to two thirds of survivors report at least one chronic health condition as a late effect of treatment. This presentation describes these effects and interventions to treat them.

Chronic graft-versus-host disease occurs in more than 50% of patients transplanted with cells from a donor. The skin is affected most frequently by GVHD. This presentation describes different types of GVHD of the skin. It also discusses the most common symptoms and promising treatments for this problem.

Bone marrow and stem cell transplant recipients have an increased risk of osteoporosis and bone fractures. Life-style changes can improve bone health, but in more serious cases, medications may be required. This presentation reviews risk factors and effective remedies for bone problems in transplant patients.

Neuropathy (nerve damage) is common after high-dose chemotherapy and a stem cell transplant. Peripheral neuropathy can cause tingling or pain in the arms, hands, legs and/or feet. Other types of neuropathy can cause symptoms ranging from dizziness when standing, problems with digestion and urination to loss of balance, numbness, and muscle atrophy.

Graft-versus-host disease occurs when a donor’s cells attack a transplant recipient’s organs and tissues. GVHD can occur throughout the gastrointestinal system as well as in the liver. This presentation describes how GVHD can attack the mouth, esophagus, stomach, large and small bowels and liver.